Skip to main content
Fig. 6 | Molecular Neurodegeneration

Fig. 6

From: Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease

Fig. 6

P021 treatment reduces soluble Aβ in 3xTg-AD mice. Reprinted from Kazim et al. [99] with permission from Elsevier. a, b ELISA quantification of soluble and insoluble Aβ 1–40 and Aβ 1–42 in the cortex revealed significant reduction of soluble Aβ with P021 treatment in 15–16 month-old/6 months treatment group but not in 21–22 month old/12 months treatment group. No effect on insoluble Aβ was found. Quantification is shown as mean ± S.E.M. from Tg-Vh (n = 5–7) and Tg-P021 (n = 6–7). c, d Representative photomicrographs illustrating thioflavin S (TS)+ plaque load in the CA1 and subiculum regions of the hippocampus from 15–16 month old/6 months treatment mice are shown. Quantification of TS+ load is shown as mean ± S.E.M. from Tg-Vh (n = 7), and Tg-P021 (n = 7). e, f Representative photomicrographs illustrating TS+ plaque load in the CA1 and subiculum regions of the hippocampus from 21–22 month old/12 months treatment mice are shown. Quantification of TS+ load is shown as mean ± S.E.M. from Tg-Vh (n = 7), and Tg-P021 (n = 6–7). *p < 0.05, **p < 0.01. Scale bar = 100 μm

Back to article page